References
- La Placa M, Ambretti S, Bonvicini F, et al. Presence of high-risk human papillomavirus genotypes in primary melanoma and acquired dysplastic melanocytic nevi. Br J Dermatol 2005;152:909–914
- Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507–2516
- Anforth R, Penas PF, Long GV. Cutanous toxicities of RAF inhibitors. Lancet Oncol 2013;14:11–18
- Oberholzer PA, Kee D, Dziunycz P, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012;30:316–321
- Lacouture M, Duvic M, Hauschild A, et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 2013;18:314–322
- Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous cell carcinoma in patients treated with BRAF inhibitors. N Engl J Med 2012;366:207–215
- Ganzenmueller T, Hage E, Yakushko Y, et al. No human virus sequences detected by next generation sequencing in benign verrucous skin tumors occurring in BRAF inhibitor treated patients. Exp Dermatol 2013;22:725–729
- Ganzenmueller T, Yakushko Y, Kluba J, et al. Next-generation sequencing fails to identify human virus sequences in cutaneous squamous cell carcinoma. Int J Cancer 2012;131:E1173–E1179
- Kent R, Glorioso S, Nordberg ML. A model for cutaneous squamous cell carcinoma in vemurafenib therapy. J La State Med Soc 2012;164:311–313
- Falchook GS, Rady P, Hymes S, et al. Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib. JAMA Dermatol 2013;149:322–326